Literature DB >> 33925284

HDL Cholesterol and Non-Cardiovascular Disease: A Narrative Review.

Emilie W Kjeldsen1,2, Liv T Nordestgaard1,2, Ruth Frikke-Schmidt1,2.   

Abstract

High density lipoprotein (HDL) cholesterol has traditionally been considered the "good cholesterol", and most of the research regarding HDL cholesterol has for decades revolved around the possible role of HDL in atherosclerosis and its therapeutic potential within atherosclerotic cardiovascular disease. Randomized trials aiming at increasing HDL cholesterol have, however, failed and left questions to what role HDL cholesterol plays in human health and disease. Recent observational studies involving non-cardiovascular diseases have shown that high levels of HDL cholesterol are not necessarily associated with beneficial outcomes as observed for age-related macular degeneration, type II diabetes, dementia, infection, and mortality. In this narrative review, we discuss these interesting associations between HDL cholesterol and non-cardiovascular diseases, covering observational studies, human genetics, and plausible mechanisms.

Entities:  

Keywords:  Alzheimer’s disease; blindness; diabetes; drusen; epidemiology; genetics; high-density lipoprotein; infection; mortality

Year:  2021        PMID: 33925284     DOI: 10.3390/ijms22094547

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  121 in total

Review 1.  Systemic and ocular fluid compounds as potential biomarkers in age-related macular degeneration.

Authors:  Eveline Kersten; Constantin C Paun; Rosa L Schellevis; Carel B Hoyng; Cécile Delcourt; Imre Lengyel; Tunde Peto; Marius Ueffing; Caroline C W Klaver; Sascha Dammeier; Anneke I den Hollander; Eiko K de Jong
Journal:  Surv Ophthalmol       Date:  2017-05-15       Impact factor: 6.048

2.  Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.

Authors:  Philip J Barter; Kerry-Anne Rye; Jean-Claude Tardif; David D Waters; S Matthijs Boekholdt; Andrei Breazna; John J P Kastelein
Journal:  Circulation       Date:  2011-07-18       Impact factor: 29.690

3.  High-density lipoproteins are a potential therapeutic target for age-related macular degeneration.

Authors:  Una L Kelly; Daniel Grigsby; Martha A Cady; Michael Landowski; Nikolai P Skiba; Jian Liu; Alan T Remaley; Mikael Klingeborn; Catherine Bowes Rickman
Journal:  J Biol Chem       Date:  2020-07-31       Impact factor: 5.157

4.  Effects of torcetrapib in patients at high risk for coronary events.

Authors:  Philip J Barter; Mark Caulfield; Mats Eriksson; Scott M Grundy; John J P Kastelein; Michel Komajda; Jose Lopez-Sendon; Lori Mosca; Jean-Claude Tardif; David D Waters; Charles L Shear; James H Revkin; Kevin A Buhr; Marian R Fisher; Alan R Tall; Bryan Brewer
Journal:  N Engl J Med       Date:  2007-11-05       Impact factor: 91.245

5.  Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study.

Authors:  Peter W F Wilson; James B Meigs; Lisa Sullivan; Caroline S Fox; David M Nathan; Ralph B D'Agostino
Journal:  Arch Intern Med       Date:  2007-05-28

6.  High Density Lipoprotein Cholesterol and the Risk of All-Cause Mortality among U.S. Veterans.

Authors:  Benjamin Bowe; Yan Xie; Hong Xian; Sumitra Balasubramanian; Mohamed A Zayed; Ziyad Al-Aly
Journal:  Clin J Am Soc Nephrol       Date:  2016-08-11       Impact factor: 8.237

7.  Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel.

Authors:  Jan Borén; M John Chapman; Ronald M Krauss; Chris J Packard; Jacob F Bentzon; Christoph J Binder; Mat J Daemen; Linda L Demer; Robert A Hegele; Stephen J Nicholls; Børge G Nordestgaard; Gerald F Watts; Eric Bruckert; Sergio Fazio; Brian A Ference; Ian Graham; Jay D Horton; Ulf Landmesser; Ulrich Laufs; Luis Masana; Gerard Pasterkamp; Frederick J Raal; Kausik K Ray; Heribert Schunkert; Marja-Riitta Taskinen; Bart van de Sluis; Olov Wiklund; Lale Tokgozoglu; Alberico L Catapano; Henry N Ginsberg
Journal:  Eur Heart J       Date:  2020-06-21       Impact factor: 29.983

8.  Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-β pathology.

Authors:  Marc Suárez-Calvet; Estrella Morenas-Rodríguez; Gernot Kleinberger; Kai Schlepckow; Miguel Ángel Araque Caballero; Nicolai Franzmeier; Anja Capell; Katrin Fellerer; Brigitte Nuscher; Erden Eren; Johannes Levin; Yuetiva Deming; Laura Piccio; Celeste M Karch; Carlos Cruchaga; Leslie M Shaw; John Q Trojanowski; Michael Weiner; Michael Ewers; Christian Haass
Journal:  Mol Neurodegener       Date:  2019-01-10       Impact factor: 14.195

9.  Effects of extended-release niacin with laropiprant in high-risk patients.

Authors:  Martin J Landray; Richard Haynes; Jemma C Hopewell; Sarah Parish; Theingi Aung; Joseph Tomson; Karl Wallendszus; Martin Craig; Lixin Jiang; Rory Collins; Jane Armitage
Journal:  N Engl J Med       Date:  2014-07-17       Impact factor: 91.245

10.  ABC transporter genes and risk of type 2 diabetes: a study of 40,000 individuals from the general population.

Authors:  Jesper Schou; Anne Tybjærg-Hansen; Holger J Møller; Børge G Nordestgaard; Ruth Frikke-Schmidt
Journal:  Diabetes Care       Date:  2012-11-08       Impact factor: 19.112

View more
  6 in total

1.  High Density Lipoproteins: Is There a Comeback as a Therapeutic Target?

Authors:  Arnold von Eckardstein
Journal:  Handb Exp Pharmacol       Date:  2022

2.  Cardiovascular, Metabolic and Inflammatory Changes after Ovariectomy and Estradiol Substitution in Hereditary Hypertriglyceridemic Rats.

Authors:  Jan Pitha; Martina Huttl; Hana Malinska; Denisa Miklankova; Hana Bartuskova; Tomas Hlinka; Irena Markova
Journal:  Int J Mol Sci       Date:  2022-03-04       Impact factor: 5.923

Review 3.  A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies.

Authors:  Jelena Vekic; Aleksandra Zeljkovic; Khalid Al Rasadi; Mustafa Cesur; José Silva-Nunes; Anca Pantea Stoian; Manfredi Rizzo
Journal:  Metabolites       Date:  2022-01-24

4.  High-Density Lipoproteins in Non-Cardiovascular Diseases.

Authors:  Ilaria Zanotti
Journal:  Int J Mol Sci       Date:  2022-08-20       Impact factor: 6.208

Review 5.  Shared Risk Factors between Dementia and Atherosclerotic Cardiovascular Disease.

Authors:  Liv Tybjærg Nordestgaard; Mette Christoffersen; Ruth Frikke-Schmidt
Journal:  Int J Mol Sci       Date:  2022-08-29       Impact factor: 6.208

6.  Remnant cholesterol/high-density lipoprotein cholesterol ratio is a new powerful tool for identifying non-alcoholic fatty liver disease.

Authors:  Yang Zou; Chong Hu; Maobin Kuang; Yuliang Chai
Journal:  BMC Gastroenterol       Date:  2022-03-24       Impact factor: 3.067

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.